UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 17, 2014
CORTEX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S
Employer
Identification No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01 Entry into a Material Definitive Agreement.
Award
of Common Stock Options
At
the meeting of the Board of Directors of the Company on July 17, 2014, the Board of Directors awarded options to purchase 5,000,000
shares of Common Stock of the Company to each of Arnold S. Lippa, Jeff E. Margolis and Robert N. Weingarten. The options were
awarded as compensation for those individuals through December 31, 2014. The awarded options vest in three equal installments
on July 17, 2014 (at issuance), September 30, 2014, and December 31, 2014, and expire on July 17, 2019. The exercise price of
the options of $0.05 per share is in excess of the closing market price of shares of Common Stock of the Company as of the date
of issuance. The Company believes and intends that a portion of the options awarded qualify as incentive stock options under the
internal revenue code of 1986, as amended. The issuance of incentive stock awards are restricted as to amount as set forth in
the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “Plan”) previously
approved by the Company’s stockholders. The form of award of the awarded options reflects this intention and the limits
under the Plan. The foregoing description of the options awarded does not purport to be complete and is qualified in its entirety
by reference to the full text of the Form of Non-Statutory Stock Option Award Agreement and Form of Incentive Stock Option Award
Agreement, a copy of each of which is attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively, and each of which is incorporated
herein by reference.
Filing
of Common Stock Award Agreement
As
previously reported by the Company in its Current Report on Form 8-K filed on April 18, 2014, the Company previously awarded shares
of Common Stock to certain of its officers and directors, including Arnold S. Lippa, Jeff E. Margolis and Robert N. Weingarten.
The Form of Restricted Stock Award Agreement used for those awards is attached hereto as Exhibit 10.3.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits required to be filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: July 23,
2014 |
CORTEX
PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/
Arnold S. Lippa |
|
|
Arnold S. Lippa |
|
|
President and
Chief Executive Officer |
EXHIBIT
INDEX
Exhibit
Number |
|
Exhibit
Description |
|
|
|
10.1 |
|
Form of Non-Statutory
Stock Option Award Agreement. |
10.2 |
|
Form of Incentive
Stock Option Award Agreement. |
10.3 |
|
Form of Restricted
Stock Award Agreement. |
Exhibit
10.1
FORM
OF NON-STATUTORY STOCK OPTION AWARD AGREEMENT
This
Stock Option Award Agreement (this “Agreement”) is made and entered into as of [DATE] by and between Cortex
Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and [PARTICIPANT NAME] (the “Participant”).
Grant
Date: ____________________________________
Exercise
Price per Share: __________________________
Number
of Option Shares: _________________________
Expiration
Date: _________________________________
1. Grant
of Option.
1.1 Grant;
Type of Option. The Company hereby grants to the Participant an option (the “Option”) to purchase the total
number of shares of Common Stock of the Company equal to the number of Option Shares set forth above, at the exercise price set
forth above. The Option is being granted pursuant to the terms of the Company’s 2014 Equity, Equity-Linked and Equity Derivative
Incentive Plan (the “Plan”). The Option is intended to be a Non-Statutory Stock Option and not an Incentive
Stock Option within the meaning of Section 422 of the Internal Revenue Code.
1.2 Consideration;
Subject to Plan. The grant of the Option is made in consideration of [the services rendered to date and] the services to be
rendered by the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but
not defined herein will have the meaning ascribed to them in the Plan.
2. Exercise
Period; Vesting.
2.1 Vesting
Schedule. The Option will become vested and exercisable with respect to [NUMBER] shares on [VESTING SCHEDULE] until the Option
is 100% vested. The unvested portion of the Option will not be exercisable on or after the Participant’s termination of
Continuous Service Status.
2.2 Expiration.
The Option will expire on the expiration date set forth above, or earlier as provided in this Agreement or the Plan.
3. Manner
of Exercise.
3.1 Election
to Exercise. To exercise the Option, the Participant (or in the case of exercise after the Participant’s death or incapacity,
the Participant’s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Administrator from time to time (the “Exercise Agreement”),
which shall set forth, inter alia:
(a) the
Participant’s election to exercise the Option;
(b) the
number of shares of Common Stock being purchased;
(c) any
restrictions imposed on the shares; and
(d) any
representations, warranties and agreements regarding the Participant’s investment intent and access to information as may
be required by the Company to comply with applicable securities laws.
If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the
Company verifying that such person has the legal right to exercise the Option.
3.2 Payment
of Exercise Price. The entire exercise price of the Option shall be payable in full at the time of exercise in any manner
designated in the Plan.
3.3 Withholding.
Prior to the issuance of shares upon the exercise of the Option, the Participant must make arrangements satisfactory to the Company
to pay or provide for any applicable federal, state and local withholding obligations of the Company. The Company has the right
to withhold from any compensation paid to a Participant.
3.4 Issuance
of Shares. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company
shall issue the shares of Common Stock registered in the name of the Participant, the Participant’s authorized assignee,
or the Participant’s legal representative, and shall deliver certificates representing the shares with the appropriate legends
affixed thereto.
4. No
Right to Continued Service; No Rights as Shareholder. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee or Consultant of the Employer. Further, nothing in the Plan or this Agreement
shall be construed to limit the discretion of the Employer to terminate the Participant’s Continuous Service Status at any
time, with or without Cause. The Participant shall not have any rights as a shareholder with respect to any shares of Common Stock
subject to the Option prior to the date of exercise of the Option.
5. Transferability.
The Option may be transferred in accordance with the terms of the Plan upon written approval by the Administrator.
6. Change
of Control.
6.1 Acceleration
of Vesting. [In the event of a Change of Control, notwithstanding any provision of the Plan or this Agreement to the contrary,
the Option shall become immediately vested and exercisable with respect to 100% of the Shares subject to the Option. To the extent
practicable, such acceleration of vesting and exercisability shall occur in a manner and at a time which allows the Participant
the ability to participate in the Change of Control with respect to the shares of Common Stock received.
OR
Unless
otherwise determined by the Administrator at the time of a Change of Control, a Change of Control shall have no effect on the
Option.]
7. Adjustments.
The shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by Section 10 of
the Plan.
8. Tax
Liability and Withholding. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related
Items is and remains the Participant’s responsibility and the Company (a) makes no representation or undertakings regarding
the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale
of any shares acquired on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant’s
liability for Tax-Related Items.
9. Compliance
with Law. The exercise of the Option and the issuance and transfer of shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable
requirements of any stock exchange on which the Company’s shares of Common Stock may be listed. No shares of Common Stock
shall be issued pursuant to this Option unless and until any then applicable requirements of state or federal laws and regulatory
agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands that the
Company is under no obligation to register the shares of Common Stock with the Securities and Exchange Commission, any state securities
commission or any stock exchange to effect such compliance.
10. Notices.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of
the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant’s address as shown in the records of the
Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to
time.
11. Governing
Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware without regard
to conflict of law principles.
12. Interpretation.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Administrator
for review. The resolution of such dispute by the Administrator shall be final and binding on the Participant and the Company.
13. Options
Subject to Plan. This Agreement is subject to the Plan as approved by the Company’s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between
any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will
govern and prevail.
14. Successors
and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure
to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant’s beneficiaries, executors, administrators and the person(s) to
whom the Option may be transferred by will or the laws of descent or distribution.
15. Severability.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and
enforceable to the extent permitted by law.
16. Discretionary
Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other
Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination
of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant’s employment with
the Company.
17. Amendment.
The Committee has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided,
that, no such amendment shall adversely affect the Participant’s material rights under this Agreement without the Participant’s
consent.
18. No
Impact on Other Benefits. The value of the Participant’s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.
19. Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
20. Acceptance.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands
the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement.
The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying
shares and that the Participant should consult a tax advisor prior to such exercise or disposition.
IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
|
CORTEX PHARMACEUTICALS, INC. |
|
[EMPLOYEE/DIRECTOR/ CONSULTANT
NAME] |
Exhibit
10.2
FORM
OF INCENTIVE STOCK OPTION AWARD AGREEMENT
This
Stock Option Award Agreement (this “Agreement”) is made and entered into as of [DATE] by and between Cortex
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [EMPLOYEE NAME] (the “Participant”).
Grant
Date: ____________________________________
Exercise
Price per Share: __________________________
Number
of Option Shares: _________________________
Expiration
Date: _________________________________
1. Grant
of Option.
1.1 Grant;
Type of Option. The Company hereby grants to the Participant an option (the “Option”) to purchase the total
number of shares of Common Stock of the Company equal to the number of Option Shares set forth above, at the exercise price set
forth above. The Option is being granted pursuant to the terms of the Company’s 2014 Equity, Equity-Linked and Equity Derivative
Incentive Plan (the “Plan”). The Option is intended to be an Incentive Stock Option within the meaning of Section
422 of the Code, although the Company makes no representation or guarantee that the Option will qualify as an Incentive Stock
Option. To the extent that the aggregate Fair Market Value (determined on the Grant Date) of the shares of Common Stock with respect
to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under all plans
of the Company and its Affiliates) exceeds $100,000, the Options or portions thereof which exceed such limit (according to the
order in which they were granted) shall be treated as Non-Statutory Stock Options.
1.2 Consideration;
Subject to Plan. The grant of the Option is made in consideration of the services [rendered to date and] to be rendered by
the Participant to the Company and is subject to the terms and conditions of the Plan. Capitalized terms used but not defined
herein will have the meaning ascribed to them in the Plan.
2. Exercise
Period; Vesting.
2.1 Vesting
Schedule. The Option will become vested and exercisable with respect to [NUMBER] shares on [VESTING SCHEDULE] until the Option
is 100% vested. The unvested portion of the Option will not be exercisable on or after the Participant’s termination of
Continuous Service Status.
2.2 Expiration.
The Option will expire on the expiration date set forth above, or earlier as provided in this Agreement or the Plan.
3. Termination
of Continuous Service. Determination of termination of Continuous Service Status shall be governed by and as defined in the
Plan.
4. Manner
of Exercise.
4.1 Election
to Exercise. To exercise the Option, the Participant (or in the case of exercise after the Participant’s death or incapacity,
the Participant’s executor, administrator, heir or legatee, as the case may be) must deliver to the Company an executed
stock option exercise agreement in such form as is approved by the Administrator from time to time (the “Exercise Agreement”),
which shall set forth, inter alia:
(a) the
Participant’s election to exercise the Option;
(b) the
number of shares of Common Stock being purchased;
(c) any
restrictions imposed on the shares; and
(d) any
representations, warranties and agreements regarding the Participant’s investment intent and access to information as may
be required by the Company to comply with applicable securities laws.
If
someone other than the Participant exercises the Option, then such person must submit documentation reasonably acceptable to the
Company verifying that such person has the legal right to exercise the Option.
4.2 Payment
of Exercise Price. The entire exercise price of the Option shall be payable in full at the time of exercise in any manner
designated in the Plan.
4.3 Withholding.
If the Company, in its discretion, determines that it is obligated to withhold any tax in connection with the exercise of the
Option, the Participant must make arrangements satisfactory to the Company to pay or provide for any applicable federal, state
and local withholding obligations of the Company. The Company has the right to withhold from any compensation paid to a Participant.
4.4 Issuance
of Shares. Provided that the Exercise Agreement and payment are in form and substance satisfactory to the Company, the Company
shall issue the shares of Common Stock registered in the name of the Participant, the Participant’s authorized assignee,
or the Participant’s legal representative, and shall deliver certificates representing the shares with the appropriate legends
affixed thereto.
5. No
Right to Continued Employment; No Rights as Shareholder. Neither the Plan nor this Agreement shall confer upon the Participant
any right to be retained in any position, as an Employee of the Employer. Further, nothing in the Plan or this Agreement shall
be construed to limit the discretion of the Employer to terminate the Participant’s Continuous Service Status at any time,
with or without Cause. The Participant shall not have any rights as a shareholder with respect to any shares of Common Stock subject
to the Option prior to the date of exercise of the Option.
6. Transferability.
The Option is not transferable by the Participant other than to a designated beneficiary upon the Participant’s death or
by will or the laws of descent and distribution, and is exercisable during the Participant’s lifetime only by him or her.
No assignment or transfer of the Option, or the rights represented thereby, whether voluntary or involuntary, by operation of
law or otherwise (except to a designated beneficiary, upon death, by will or the laws of descent or distribution) will vest in
the assignee or transferee any interest or right herein whatsoever, but immediately upon such assignment or transfer the Option
will terminate and become of no further effect.
7. Change
of Control.
7.1 Acceleration
of Vesting. [In the event of a Change of Control, notwithstanding any provision of the Plan or this Agreement to the contrary,
the Option shall become immediately vested and exercisable with respect to 100% of the Shares subject to the Option. To the extent
practicable, such acceleration of vesting and exercisability shall occur in a manner and at a time which allows the Participant
the ability to participate in the Change of Control with respect to the shares of Common Stock received.
OR
Unless
otherwise determined by the Administrator at the time of a Change of Control, a Change of Control shall have no effect on the
Option.]
8. Adjustments.
The shares of Common Stock subject to the Option may be adjusted or terminated in any manner as contemplated by Section 10 of
the Plan.
9. Tax
Liability and Withholding. Notwithstanding any action the Company takes with respect to any or all income tax, social insurance,
payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related
Items is and remains the Participant’s responsibility and the Company (a) makes no representation or undertakings regarding
the treatment of any Tax-Related Items in connection with the grant, vesting, or exercise of the Option or the subsequent sale
of any shares acquired on exercise; and (b) does not commit to structure the Option to reduce or eliminate the Participant’s
liability for Tax-Related Items.
10. Qualification
as an Incentive Stock Option. It is understood that this Option is intended to qualify as an incentive stock option as defined
in Section 422 of the Code to the extent permitted under Applicable Law. Accordingly, the Participant understands that in order
to obtain the benefits of an incentive stock option, no sale or other disposition may be made of shares for which incentive stock
option treatment is desired within one (1) year following the date of exercise of the Option or within two (2) years from the
Grant Date. The Participant understands and agrees that the Company shall not be liable or responsible for any additional tax
liability the Participant incurs in the event that the Internal Revenue Service for any reason determines that this Option does
not qualify as an incentive stock option within the meaning of the Code.
11. Disqualifying
Disposition. If the Participant disposes of the shares of Common Stock prior to the expiration of either two (2) years from
the Grant Date or one (1) year from the date the shares are transferred to the Participant pursuant to the exercise of the Option
(a “Disqualifying Disposition”), the Participant shall notify the Company in writing within thirty (30) days
after such disposition of the date and terms of such disposition. The Participant also agrees to provide the Company with any
information concerning any such dispositions as the Company requires for tax purposes.
12. Compliance
with Law. The exercise of the Option and the issuance and transfer of shares of Common Stock shall be subject to compliance
by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable
requirements of any stock exchange on which the Company’s shares of Common Stock may be listed. No shares of Common Stock
shall be issued pursuant to this Option unless and until any then applicable requirements of state or federal laws and regulatory
agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands that the
Company is under no obligation to register the shares of Common Stock with the Securities and Exchange Commission, any state securities
commission or any stock exchange to effect such compliance.
13. Notices.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of
the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Participant under this
Agreement shall be in writing and addressed to the Participant at the Participant’s address as shown in the records of the
Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to
time.
14. Governing
Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware without regard
to conflict of law principles.
15. Interpretation.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Administrator
for review. The resolution of such dispute by the Administrator shall be final and binding on the Participant and the Company.
16. Options
Subject to Plan. This Agreement is subject to the Plan as approved by the Company’s shareholders. The terms and provisions
of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between
any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will
govern and prevail.
17. Successors
and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure
to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Participant and the Participant’s beneficiaries, executors, administrators and the person(s) to
whom the Option may be transferred by will or the laws of descent or distribution.
18. Severability.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and
enforceable to the extent permitted by law.
19. Discretionary
Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Option in this Agreement does not create any contractual right or other right to receive any Options or other
Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination
of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant’s employment with
the Company.
20. Amendment.
The Administrator has the right to amend, alter, suspend, discontinue or cancel the Option, prospectively or retroactively; provided,
that, no such amendment shall adversely affect the Participant’s material rights under this Agreement without the Participant’s
consent.
21. No
Impact on Other Benefits. The value of the Participant’s Option is not part of his or her normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.
22. Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
23. Acceptance.
The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands
the terms and provisions thereof, and accepts the Option subject to all of the terms and conditions of the Plan and this Agreement.
The Participant acknowledges that there may be adverse tax consequences upon exercise of the Option or disposition of the underlying
shares and that the Participant should consult a tax advisor prior to such exercise or disposition.
IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
|
CORTEX
PHARMACEUTICALS, INC. |
Exhibit
10.3
FORM
OF RESTRICTED STOCK AWARD AGREEMENT
This
Restricted Stock Award Agreement (this “Agreement”) is made and entered into as of [DATE] (the “Grant
Date”) by and between Cortex Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [GRANTEE
NAME] (the “Grantee”).
WHEREAS,
the Company has adopted the 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “Plan”) pursuant
to which awards of Restricted Stock may be granted; and
WHEREAS,
the Administrator has determined that it is in the best interests of the Company and its shareholders to grant the award of Restricted
Stock provided for herein.
NOW,
THEREFORE, the parties hereto, intending to be legally bound, agree as follows:
1. Grant
of Restricted Stock. Pursuant to Section 8 of the Plan, the Company hereby issues to the Grantee on the Grant Date a Restricted
Stock Award consisting of, in the aggregate, [NUMBER] shares of Common Stock of the Company (the “Restricted Stock”),
on the terms and conditions and subject to the restrictions set forth in this Agreement and the Plan. Capitalized terms that are
used but not defined herein have the meaning ascribed to them in the Plan.
2. Consideration.
The grant of the Restricted Stock is made in consideration of the services rendered to date and to be rendered by the Grantee
to the Company.
3. Restricted
Period; Vesting.
3.1 Except
as otherwise provided herein, provided that the Grantee remains in Continuous Service through the applicable vesting date, the
Restricted Stock will vest in accordance with the following schedule:
Vesting
Date |
|
Shares
of Common Stock |
|
|
|
[ANY
DATE ON OR AFTER GRANT DATE] |
|
[0%
to 100%] |
|
|
|
[ANY
DATE AFTER VESTING DATE IN FIRST TRANCHE] |
|
[1
- PERCENT VESTING IN FIRST TRANCHE] |
The
period over which the Restricted Stock vests is referred to as the “Restricted Period.”
3.2 The
foregoing vesting schedule notwithstanding, if the Grantee’s Continuous Service Status terminates for any reason at any
time before all of his or her Restricted Stock has vested, the Grantee’s unvested Restricted Stock shall be automatically
forfeited upon such termination of Continuous Service Status and neither the Company nor any Affiliate shall have any further
obligations to the Grantee under this Agreement.
3.3 [The
foregoing vesting schedule notwithstanding, upon the occurrence of a Change of Control, 100% of the unvested Restricted Stock
shall vest as of the date of the Change of Control.
OR
Unless
otherwise determined by the Administrator at the time of a Change of Control, a Change of Control shall have no effect on the
Restricted Stock.]
4. Restrictions.
Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period, the Restricted Stock or the rights
relating thereto may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Grantee.
Any attempt to assign, alienate, pledge, attach, sell or otherwise transfer or encumber the Restricted Stock or the rights relating
thereto during the Restricted Period shall be wholly ineffective and, if any such attempt is made, the Restricted Stock will be
forfeited by the Grantee and all of the Grantee’s rights to such shares shall immediately terminate without any payment
or consideration by the Company.
5. Rights
as Shareholder; Dividends.
5.1 The
Grantee shall be the record owner of the Restricted Stock until the shares of Common Stock are sold or otherwise disposed of,
and shall be entitled to all of the rights of a shareholder of the Company including, without limitation, the right to vote such
shares and receive all dividends or other distributions paid with respect to such shares. Notwithstanding the foregoing, any dividends
or other distributions shall be subject to the same restrictions on transferability as the shares of Restricted Stock with respect
to which they were paid.
5.2 The
Company may issue stock certificates or evidence the Grantee’s interest by using a restricted book entry account with the
Company’s transfer agent. Physical possession or custody of any stock certificates that are issued shall be retained by
the Company until such time as the Restricted Stock vests.
5.3 If
the Grantee forfeits any rights he has under this Agreement in accordance with Section 3, the Grantee shall, on the date of such
forfeiture, no longer have any rights as a shareholder with respect to the Restricted Stock and shall no longer be entitled to
vote or receive dividends on such shares.
6. No
Right to Continued Service. Neither the Plan nor this Agreement shall confer upon the Grantee any right to be retained in
any position, as an Employee or Consultant of the Employer. Further, nothing in the Plan or this Agreement shall be construed
to limit the discretion of the Employer to terminate the Grantee’s Continuous Service Status at any time, with or without
Cause.
7. Adjustments.
If any change is made to the outstanding Common Stock or the capital structure of the Company, if required, the shares of Common
Stock shall be adjusted or terminated in any manner as contemplated by Section 10 of the Plan.
8. Tax
Liability and Withholding.
8.1 The
Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to
the Grantee pursuant to the Plan, the amount of any required withholding taxes in respect of the Restricted Stock and to take
all such other action as the Administrator deems necessary to satisfy all obligations for the payment of such withholding taxes.
8.2 Notwithstanding
any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding
(“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Grantee’s
responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in
connection with the grant or vesting of the Restricted Stock or the subsequent sale of any shares; and (b) does not commit to
structure the Restricted Stock to reduce or eliminate the Grantee’s liability for Tax-Related Items.
9. Compliance
with Law. The issuance and transfer of shares of Common Stock shall be subject to compliance by the Company and the Grantee
with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange
on which the Company’s shares of Common Stock may be listed. No shares of Common Stock shall be issued or transferred unless
and until any then applicable requirements of state and federal laws and regulatory agencies have been fully complied with to
the satisfaction of the Company and its counsel. The Grantee understands that the Company is under no obligation to register the
shares of Common Stock with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect
such compliance.
10. Legends.
A legend may be placed on any certificate(s) or other document(s) delivered to the Grantee indicating restrictions on transferability
of the shares of Restricted Stock pursuant to this Agreement or any other restrictions that the Administrator may deem advisable
under the rules, regulations and other requirements of the Securities and Exchange Commission, any applicable federal or state
securities laws or any stock exchange on which the shares of Common Stock are then listed or quoted.
11. Notices.
Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Secretary of
the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Grantee under this
Agreement shall be in writing and addressed to the Grantee at the Grantee’s address as shown in the records of the Company.
Either party may designate another address in writing (or by such other method approved by the Company) from time to time.
12. Governing
Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Delaware without regard
to conflict of law principles.
13. Interpretation.
Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the Company to the Administrator
for review. The resolution of such dispute by the Administrator shall be final and binding on the Grantee and the Company.
14. Restricted
Stock Subject to Plan. This Agreement is subject to the Plan as approved by the Company’s shareholders. The terms and
provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict
between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the
Plan will govern and prevail.
15. Successors
and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure
to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement
will be binding upon the Grantee and the Grantee’s beneficiaries, executors, administrators and the person(s) to whom the
Restricted Stock may be transferred by will or the laws of descent or distribution.
16. Severability.
The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability
of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and
enforceable to the extent permitted by law.
17. Discretionary
Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion.
The grant of the Restricted Stock in this Agreement does not create any contractual right or other right to receive any Restricted
Stock or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification,
or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Grantee’s employment
with the Company.
18. Amendment.
The Administrator has the right to amend, alter, suspend, discontinue or cancel the Restricted Stock, prospectively or retroactively;
provided, that, no such amendment shall adversely affect the Grantee’s material rights under this Agreement without
the Grantee’s consent.
19. No
Impact on Other Benefits. The value of the Grantee’s Restricted Stock is not part of his normal or expected compensation
for purposes of calculating any severance, retirement, welfare, insurance or similar employee benefit.
20. Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute
one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic
mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial
appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
21. Acceptance.
The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read and understands the terms
and provisions thereof, and accepts the Restricted Stock subject to all of the terms and conditions of the Plan and this Agreement.
The Grantee acknowledges that there may be adverse tax consequences upon the grant or vesting of the Restricted Stock or disposition
of the underlying shares and that the Grantee has been advised to consult a tax advisor prior to such grant, vesting or disposition.
IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
|
CORTEX
PHARMACEUTICALS, INC. |
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
過去 株価チャート
から 9 2024 まで 10 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
過去 株価チャート
から 10 2023 まで 10 2024